Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTRAPLEURAL TREATMENT WITH RECOMBINANT GAMMA-INTERFERON IN EARLY-STAGE MALIGNANT PLEURAL MESOTHELIOMA
Autore:
BOUTIN C; NUSSBAUM E; MONNET I; BIGNON J; VANDERSCHUEREN R; GUERIN JC; MENARD O; MIGNOT P; DABOUIS G; DOUILLARD JY;
Indirizzi:
CONCEPT HOSP,147 BD BAILLE F-13385 MARSEILLE 5 FRANCE CTR HOSP INTERCOMMUNAL CRETEIL FRANCE ST ANTONIUS HOSP NIEUWEGEIN NETHERLANDS HOP CROIX ROUSSE F-69317 LYON FRANCE HOP BRABOIS VANDOEUVRE NANCY FRANCE HOP SABOURIN CLERMONT FERRAND FRANCE HOP LAENNEC NANTES FRANCE CTR RENE GAUDUCHEAU ST HERBLAIN FRANCE
Titolo Testata:
Cancer
fascicolo: 9, volume: 74, anno: 1994,
pagine: 2460 - 2467
SICI:
0008-543X(1994)74:9<2460:ITWRGI>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
188 CONSECUTIVE PATIENTS; INTERFERON-GAMMA; OVARIAN-CARCINOMA; INTRACAVITARY CISPLATIN; MULTIMODALITY THERAPY; IMMUNE INTERFERON; DIFFUSE; LYMPHOKINE; EFFUSIONS; CANCER;
Keywords:
MESOTHELIOMA; CYTOKINES; GAMMA-INTERFERON; THORACOSCOPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
54
Recensione:
Indirizzi per estratti:
Citazione:
C. Boutin et al., "INTRAPLEURAL TREATMENT WITH RECOMBINANT GAMMA-INTERFERON IN EARLY-STAGE MALIGNANT PLEURAL MESOTHELIOMA", Cancer, 74(9), 1994, pp. 2460-2467

Abstract

Background. This report presents the results of a prospective multi-institutional study of intrapleural treatment with gamma-interferon in patients with Butchart's Stages I and II epithelial or mixed malignantpleural mesothelioma. Methods. Interferon was administered at a dose of 40 million units twice a week for 8 weeks intrapleurally via a catheter or an implantable port. Thoracoscopic or surgical biopsy was performed if computed tomography scan 2 weeks after the end of treatment demonstrated a reduction in tumor size. Survival was calculated after afollowup of at least 18 months. Prognostic factors were identified byunivariate and multivariate analyses (Cox model). Results. Eighty-nine patients were included over 46 months. Eight histologically confirmed complete responses and nine partial responses with at least a 50% reduction in tumor size were obtained. The overall response rate was 20%. Most responses were achieved in patients with early stage disease. The response rate for patients with Stage I disease was 45%. Tolerance of interferon was good. Treatment was performed on an outpatient basis. The main side effects were hyperthermia, liver toxicity, neutropenia, and catheter-related infection. Conclusions. Gamma-interferon is effective mainly Stage I mesothelioma, especially if the tumor is confined to the parietal or diaphragmatic pleura (Stage IA).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 23:39:50